GSK pays CureVac $430M for mRNA vaccines against flu and COVID—as partner lays off 30%

GSK pays CureVac $430M for mRNA vaccines against flu and COVID—as partner lays off 30% ntaylor Wed, 07/03/2024 - 04:43